Archive for April, 2009

Access to the “wisdom of peers”

One of the multiple contributions of OA is the removal of price barriers that prevent many people (especially patients, their families and friends, and perhaps their physicians and other caregivers) from having convenient access to the primary quality-controlled research literature. The major challenge for OA advocates is to foster ways to enhance  access to the peer-reviewed literature, mainly for the benefit of other researchers and scholars, but also as a source of evidence-based information for everyone else. The term “Information Therapy” (Ix) has been used as a label for the provision of such evidence-based information by doctors or other healthcare professionals.

However, there’s another kind of information, based on “experiential data“, that can also be of great value to patients and their families and friends.  This is information based on the personal experience of individuals with their own illness, or that of people close to them.  Judy Feder has used the words “the wisdom of my peers” to describe such “experiential data“.  See her comment on: When is “Information Therapy” Simply Learning?, e-patients.net, April 7, 2009.

The current definition of Information Therapy in Wikipedia is: “Information therapy is a healthcare term,[1] describing the timely prescription and availability of evidence-based health information to meet individuals’ specific needs and support sound decision making“.  This entry in Wikipedia is currently marked as in need of revision. For example, this warning is currently attached to the entry: “This article may contain wording that promotes the subject in a subjective manner without imparting real information“.

For an interesting discussion of the meaning of terms like “Information Therapy” and “Health 2.0”, see the full text (including the many comments) of: When is “Information Therapy” Simply Learning? by John Grohol, e-patients.net, April 6, 2009.

Two examples of comments:

Gilles Frydman on April 7th, 2009. Excerpts:

Hopefully soon we will all agree that there are at least 2 parallels medical realms. The main one (in terms of number of patients and costs) which starts mostly as a perfect algorithm. It’s the famous medical world of the big chronic diseases. (Many thanks to David Kibbe for expressing this so well in a recent blog post).

Then the second one, where things are completely different. No algorithm. A world of darkness where patients have to become aware that most of the clinicians are half-blind and know very little. That is of course where systems like ACOR shine and save countless lives. That is also where the principle of Information Therapy falls completely flat.

Thinking that your general practitioner will provide you better information about testicular cancer than the very well organized patient-centered and patient-produced information sites like the TCRC (Testicular Cancer Resource Center http://tcrc.acor.org) is ABSURD! The doctor should just say “Go to TCRC” and be done with the Information Therapy portion of their encounter. And not be reimbursed for that wonderful piece of advice.

[There’s a reference to “ACOR” in the above excerpts. For information about ACOR, see: About ACOR, Patient-Centered Wikis].

Gunther Eysenbach on April 7th, 2009. Excerpts:

I don’t think Ix was originally conceptualized as “self-prescription”. Rather, Ix seemd to target the “intermediary”.

…..

Now in my view, Health 2.0 / Medicine 2.0 is almost the exact opposite, opening a new way to inform people and to inject trust – without a “trusted intermediary”, by harnessing peers, the wisdom of the crowds, etc., who are in many cases BYPASSING the trusted expect/authority/intermediary. I have called this apomediation (http://bit.ly/yRoXX http://bit.ly/6E5qL). In the apomediated environment, trust and credibility is earned not through authority and formal degrees, but through first-hand experience (”street cred”), etc.

Comment: At present, journals continue to provide, via peer-review mechanisms, a crucial “trusted intermediary”. “Apomediation” provides an alterative. An excerpt from the abstract of Gunther Eysenbach’s article (http://bit.ly/yRoXX): “It is hypothesized that in an apomediated environment, tools, influential peers and opinion leaders are the primary conveyors of trust and credibility. In this environment, apomediary credibility may become equally or more important than source credibility or even message credibility.” Perhaps the OA movement in general, and Open Access News in particular, provides examples of an “apomediated environment“?

Advertisements

Leave a Comment

Are prominent publishers experimenting with OA?

Three examples, from 3 different publishers:

1) A viewing today of the 2009 Reviews archive of Nature Reviews Cancer revealed 4 articles, in the archive for April 2009, where the full text “is available free as a special feature to registered visitors“. They are:

Microenvironmental regulation of metastasis by Johanna A Joyce and Jeffrey W Pollard; Learning therapeutic lessons from metastasis suppressor proteins by Steven Christopher Smith and Dan Theodorescu; Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits by Kornelia Polyak and Robert A Weinberg; Metastasis: from dissemination to organ-specific colonization by Don X Nguyen, Paula D Bos and Joan Massagué.

2) A viewing today of the Genetics collection of the New England Journal of Medicine revealed 6 Gratis OA articles, all published at www.nejm.org on April 15, 2009. They are:

Genomewide Association Studies and Human Disease by John Hardy and Andrew Singleton; Genetic Risk Prediction — Are We There Yet? by Peter Kraft and David J Hunter; Genomewide Association Studies — Illuminating Biologic Pathways by Joel N Hirschhorn; Common Genetic Variation and Human Traits by David B Goldstein; Genomewide Association Studies of Stroke by M Arfan Ikram and 45 co-authors; Crohn’s Disease, Autophagy, and the Paneth Cell by Daniel J Klionsky.

3) A viewing today of the Site Map for Cell Press journals led me to the Archive section for the journal Cancer Cell. I then browsed the current issue (7 April 2009, Volume 15, Issue 4). One “Featured Article” was labeled “Free“. It was: Rb Regulates DNA Damage Response and Cellular Senescence through E2F-Dependent Suppression of N-Ras Isoprenylation by Awad Shamma and 7 co-authors (page 255). However, when the same article was accessed via it’s digital object identifier (DOI), at: dx.doi.org/10.1016/j.ccr.2009.03.001, I could not obtain access to the free full text.

However, when I checked access to the other 12 articles in this same issue, I was able to access the free full text of all of them. One example: Lessons Learned from the Study of JunB: New Insights for Normal and Leukemia Stem Cell Biology by Monica L Guzman and Craig T Jordan (page 252). Again, access via the DOI (dx.doi.org/10.1016/j.ccr.2009.03.008) didn’t provide a route to the free full text.

Comment: Which of the examples listed above will be Gratis OA on an ongoing basis? I’ll plan to check the links included in this post at later dates, to try to obtain an answer to this question.

Comments (2)

Life sciences video methods journal goes closed access

JoVE Leaves Open Access Behind by Philip Davis, The Scholarly Kitchen, April 6, 2009. Excerpts:

The Journal of Visualized Experiments (JoVE) has implemented a subscription model, ending a short reign of free access to high-quality scientific videos.

…..

Institutional subscriptions now range from $1,000 for small colleges to $2,400 for PhD-granting institutions, prices which are in league with other commercial scientific journals.  In addition, authors are charged $1,500 per article for video production services ($500 without), and there are open access options: $3,000/article with production services ($2,000 without).

See also: Life sciences video methods journal goes closed access by Elie Dolgin, TheScientist.com, April 6, 2009 [Free registration required]. Excerpt:

“To continue the [open access] approach, we would have to ask academic labs to pay us $6000 per video to cover our operation costs, and that’s simply not possible today,” Moshe Pritsker, CEO and editor-in-chief of JoVE, told The Scientist. “We like open access, we just can’t survive on it.”

Comments (1)